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Streptococcus pneumoniae infections are a
major cause of illness and death worldwide.
Penicillin-resistant S. pneumoniae were first
described in 1967 (1). Since then, the proportions
of  isolates resistant to penicillin and other
antimicrobial agents have increased worldwide
(2-5). In the United States, the combined
percentage of S. pneumoniae isolates with either
intermediate (MIC = 0.1-1.0  µg/ml) or high (MIC
2.0  µg/ml) levels of penicillin resistance is higher
than 60% in some areas (5). Strains with
multidrug resistance to penicillins, macrolides,
sulfonamides, and third-generation cephalospor-
ins have been well documented (3,5-9). Despite
the increasing proportion of drug-resistant
S. pneumoniae and the importance of knowing
the drug resistance status in determining
empiric therapy, community-specific surveillance
for drug-resistant S. pneumoniae is limited and
its proportion is unknown in many areas (10,11).
Active surveillance for invasive S. pneumoniae
disease includes collection of isolates, central-
ized susceptibility testing, and collection of
patient data (4).
Although such a resource-intensive system
for providing community-specific and case-
specific  S. pneumoniae data is beyond the means
of most local and many state health agencies,
hospital-specific data already exist in many
areas. Many hospital laboratories perform
antimicrobial susceptibility testing on
S. pneumoniae isolates from sterile and nonsterile
sites, and results are often tabulated for local
clinicians in a summary table called an
antibiogram. Antibiogram data represent inva-
sive and noninvasive S. pneumoniae disease
isolates collected from normally sterile and
nonsterile sites; may include multiple isolates
from the same patient; and are based on hospital
laboratory antimicrobial susceptibility testing, a
process that may differ between laboratories. In
contrast, S. pneumoniae active surveillance data
are limited to invasive disease isolates collected
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With the emergence of drug-resistant Streptococcus pneumoniae, community-
specific antimicrobial susceptibility patterns have become valuable determinants of
empiric therapy for S. pneumoniae infections. Traditionally, these patterns are tracked
by active surveillance for invasive disease, collection of isolates, and centralized
susceptibility testing. We investigated whether a simpler and less expensive method—
aggregating existing hospital antibiograms—could provide community-specific
antimicrobial susceptibility data. We compared 1996 active surveillance data with
antibiogram data from hospital laboratories in Portland, Oregon. Of the 178
S. pneumoniae active surveillance isolates, 153 (86% [95% confidence interval (CI) =
80% to 91%]) were susceptible to penicillin. Of the 1,092 aggregated isolates used by
hospitals to generate antibiograms, 921 (84% [95% CI = 82%-87%]) were susceptible
to penicillin. With the exception of one hospital’s erythromycin susceptibility results,
hospital-specific S. pneumoniae susceptibilities to penicillin, cefotaxime, trimethoprim-
sulfamethoxazole, and erythromycin from the two methods were statistically
comparable. Although yielding fewer data than active surveillance, antibiograms
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from normally sterile sites, specifically exclude
duplicate isolates collected from the same
patient, and are based on a centralized and
standardized susceptibility testing protocol.
We examined preexisting antibiogram data
to assess if they could provide local health
agencies with an accurate, inexpensive means of
estimating the community-specific proportion of
drug-resistant  S. pneumoniae. The Oregon
Health Division performs active surveillance for
drug-resistant  S. pneumoniae through a coop-
erative agreement with the Centers for Disease
Control and Preventions Emerging Infections
Program. We conducted a cross-sectional survey
of the 12 hospital laboratories that serve the
Portland Tri-County area (Multnomah, Wash-
ington, and Clackamas counties, population 1.2
million) and compared 1996 Portland
S. pneumoniae susceptibility results and costs of
the aggregated antibiogram surveillance system
with the S. pneumoniae susceptibility results
and costs of our active surveillance system. We
determined the community-specific proportion of
S. pneumoniae susceptible to penicillin and
performed a limited analysis of hospital-specific
susceptibilities to cefotaxime, trimethoprim-
sulfamethoxazole, and erythromycin.
Methods
Active Surveillance
Case Definition
Our goal was to determine the proportion of
drug-resistant isolates among all S. pneumoniae
isolates collected by the active surveillance
system in 1996. Therefore, an active surveillance
case was defined as an S. pneumoniae isolate
from a normally sterile site collected from a
Portland Tri-County resident in 1996 and
analyzed at a Portland Tri-County hospital
microbiology laboratory.
Surveillance Protocol
All Portland-area hospital microbiology
laboratories were asked to send all S. pneumoniae
sterile-site isolates from both inpatients and
outpatients to the Oregon State Public Health
Laboratory. Health Department staff regularly
contacted each laboratory to assess interim
isolate recovery rates and to encourage ongoing
participation in the surveillance system and (twice
a year) performed on-site laboratory audits to
compare the  number of patients with invasive
S. pneumoniae infections with the number of
isolates submitted to the state laboratory.
To avoid duplication, only one isolate from
each patient was sent to the reference
laboratory, even if multiple isolates were
obtained from the same person. Isolates were
sent twice a year from the Oregon State Public
Health Laboratory to a national reference
laboratory for antimicrobial susceptibility test-
ing by National Committee for Clinical
Laboratory Standards broth microdilution proto-
cols (12). S. pneumoniae antimicrobial-suscepti-
bility percentages for Portland were calculated
from the national reference laboratory results.
Invasive cases did not have reference laboratory
susceptibility testing if the hospital laboratory
did not forward the isolate to the Oregon State
Public Health Laboratory or if the isolates
received by the Oregon or the reference
laboratory were not viable.
Cost Calculations
Annual costs for this surveillance system
included direct and indirect health department
staff costs and the expense of isolate storage,
processing, and transport incurred by the
Oregon State Public Health Laboratory and the
national reference laboratory. Hospital labora-
tory isolate testing, which would have been
performed regardless of our request for
surveillance data, were not included in these
calculations. Time calculations included labora-
tory audits, patient chart reviews, data entry
and analysis, coordination of isolate movement,
and communication among hospital laboratories,
the health department, the state public health
laboratory and the reference laboratory.
Antibiogram Surveillance
Case Definition
An antibiogram case was defined as any
S. pneumoniae isolate identified in 1996 by a
Portland Tri-County hospital microbiology
laboratory that was tabulated on the respective
1996  S. pneumoniae antibiogram. Specimens
were submitted from inpatients and outpatients
and from sterile and nonsterile sites.
Surveillance Protocol
We requested antibiograms from all 12
Portland Tri-County hospital laboratories.690 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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Table 1. Streptococcus pneumoniae penicillin suscepti-
bility as determined by two surveillance methods,
Portland, Oregon, 1996
  Active surveillance    Antiobiograms
No. Susceptible No. Susceptible
Hospital isolates N % isolates N %
A      a      20   17 85
B   34   29 85    134 112 84
C   59   52 88    274 227 83
D     6     4 67    120   89 74
E   12   11 92      41   34 83
F      a      61   58 95
G   33   28 85    110 100 91
H   11   10 91    161 137 85
I     8     6 75      64   56 88
J     7     6 86    107   91 85
K     6     5 83        b
L     2     2 100        b
Total 178 153 86 1,092 921 84
aNo isolates submitted to the Oregon Public Health
Laboratory.
bAntibiogram data not available from hospital.
Figure. Hospital-specific Streptococcus pneumoniae
penicillin-susceptibility determined by antibiogram
and active surveillance, Portland, Oregon, 1996.
Antibiogram data were aggregated to produce
antimicrobial susceptibility percentages for the
Portland area. All susceptibility testing was
performed at individual hospital laboratories.
We did not routinely survey laboratory techniques
or reporting criteria, nor did the Oregon State
Public Health Laboratory perform confirmation
susceptibility testing of any hospital isolates.
Cost Calculations
The cost of the antibiogram method included
direct and indirect health department staff
expenses but excluded the cost of hospital
laboratory isolate testing, a process performed
regardless of our surveillance requests. Time
calculations included staff time spent request-
ing antibiograms and performing data entry
and analysis.
Statistical Methods
The Mantel-Haenzel chi-square and Fishers
exact tests were used to compare the proportions
of susceptible S. pneumoniae isolates deter-
mined by the two surveillance methods. P values
£0.05 were considered statistically significant.
Statistical calculations were performed by using
Epi-Info (Epi-Info version 6.04b; Centers for
Disease Control and Prevention, Atlanta, GA).
Findings
Penicillin
Of the 12 Portland-area hospital laboratories
participating in the active surveillance system,
10 (83%) submitted isolates to our active
surveillance system in 1996. One hospital (A)
had no sterile-site isolates in 1996. A second
hospital (F) had two sterile-site isolates but did
not submit them to the state laboratory. Of 266
invasive S. pneumoniae infections identified by
health department staff through audits, 178
(67%)  S. pneumoniae isolates were tested by the
reference laboratory. Of the 88 identified cases
that were not analyzed by the reference
laboratory, in 81 cases the hospital did not
submit an isolate to the state laboratory, and in 7
the isolate submitted was not viable. The number
of isolates collected from each hospital was 2 to
59 (Table 1). The mean and median numbers of
active surveillance isolates collected per hospital
were 18 and 9.5, respectively. Of the 178 isolates
tested, 153 (86% [95% CI = 80% to 91%]) were
susceptible to penicillin (MIC  0.06 µg/ml).
Penicillin antibiogram data were collected
from 10 (83%) of 12 Portland-area hospitals
(Table 1). Eight of the 10 hospitals  listed only
the proportion of susceptible S. pneumoniae
isolates on their antibiogram and did not
specify the number of intermediate- or high-
resistance isolates. Of the aggregated 1,092
S. pneumoniae isolates used by Portland-area
hospitals to generate penicillin antibiogram
data, 921 (84% [95% CI = 82% to 86%]) were
listed as susceptible to penicillin.
The proportion of penicillin-susceptible
isolates at each hospital was 67% to 100% by the
active surveillance method and  74% to 95% by
antibiogram data (Figure). The median hospital-
specific difference between the two methods691 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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Table 2. Streptococcus pneumoniae susceptibility to cefotaxime, trimethoprim-sulfamethoxazole, and erythromycin, by two surveillance
methods, Portland, Oregon, 1996
Cefotaxime Trimethoprim-Sulfamethoxazole Erythromycin
Active surveillance Antibiograms Active surveillance Antiobiograms Active surveillance Antiobiograms
  No. No. No.   No. No. No.
Hos-   iso- Susceptible iso- Susceptible  iso- Susceptible    iso- Susceptible   iso- Susceptible   iso- Susceptible
pital lates   N   % lates  N % lates N % lates N % lates N % lates N %
A      a      b      a      b     a b
B   34   32   94   10     8 80   34   26   76      b   34   33   97 134 126   94
C   59   54   92 274 255 93   59   49   83 274 230 84   59   57   97 274 230   84
D     6     4   67 120 112 93     6     3   50     6     5   83 120   88   73
E   12   12 100      b   12     9   75   16   13 81   12   12 100   42   39   93
F      a   61   59 97      a      b      a   61   56   92
G   33   31   94 110 105 95   33   27   82      b   33   30   91 110 100   91
H   11   11 100    -   11   10   91      b   11   11 100      b
I     8     7   88    -     8     6   75      b     8     8 100      b
J     7     6   86    -     7     5   71   10     8 80     7     6   86   10   10 100
K     6     6 100    -     6     4   67      b     6     5   83      b
L     2     2 100    -     2     2 100      b     2     2 100      b
Total 178 165   93 575 539 94 178 141   79 300 251 84 178 169   95 751 649   86
aIsolates submitted to the Oregon Public Health Laboratory.
bAntibiogram data not available from hospital.
was 6%. In no instance did hospital-specific
penicillin-susceptibility estimates from the two
methods differ statistically (p >0.05). We found
no statistical difference between the overall
S. pneumoniae penicillin-susceptibility propor-
tion determined by active surveillance and by the
antibiogram method (p >0.05).
Other Antibiotics
We compared active surveillance and
antibiogram  S. pneumoniae susceptibilities to
cefotaxime, trimethoprim-sulfamethoxazole, and
erythromycin (Table 2). Of the 178 isolates
collected and tested through the active surveil-
lance system, 165 (93% [95% CI = 88% to 96%])
were susceptible to cefotaxime (MIC  0.50  µg/ml),
141 (79% [95% CI = 73% to 85%]) were
susceptible to trimethoprim (MIC  0.50  µg/ml)-
sulfamethoxazole (MIC 9.50  µg/ml), and 169
(95% [95% CI = 91% to 98%]) were susceptible to
erythromycin (MIC  0.50  µg/ml).
In hospitals where antibiogram data were
available for cefotaxime, trimethoprim-
sulfamethoxazole, and erythromycin, 539 (94%)
of 575 aggregated isolates (95% CI = 91% to 95%)
were susceptible to cefotaxime, 251 (84%) of 300
isolates (95% CI = 79% to 88%) were susceptible
to trimethoprim-sulfamethoxazole, and 649
(86%) of 751 isolates (95% CI = 84% to 89%) were
susceptible to erythromycin. Hospital-specific
antibiogram and active surveillance data from
four institutions were available for direct
comparison for cefotaxime and from three
institutions for trimethoprim-sulfamethoxazole.
In each instance, the hospital-specific proportion
of  S. pneumoniae isolates susceptible to
cefotaxime or trimethoprim-sulfamethoxazole
did not differ significantly by surveillance
method. We were able to directly compare
S. pneumoniae erythromycin susceptibility by
antibiogram and active surveillance at six
hospitals. The proportions of erythromycin-
susceptible  S. pneumoniae isolates determined
by each surveillance method were statistically
comparable in five of the six hospitals (p >0.05).
One hospital (C) had a significantly higher
proportion (p = 0.01) of erythromycin-
susceptible isolates determined by active
surveillance (97% [95% CI = 88% to 100%])
than reported by the corresponding antibiogram
(84% [95% CI = 79% to 88%]).
Cost Comparison
The antibiogram survey required 20 hours of
health department staff time, for a total cost of
$700: $650 for personnel expenses and $50 for
miscellaneous support expenses. The active
surveillance method required 570 hours of staff
time and cost $52,000: $40,000 for direct and
indirect personnel expenses and $12,000 for
laboratory costs.
Conclusions
Accurate, community-specific drug-resistant
S. pneumoniae data are important for several
reasons. First, most outpatient illnesses caused692 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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by  S. pneumoniae are treated empirically,
without identification of the organism. Commu-
nity-specific data may be a valuable determinant
of empiric therapy for these infections and of
initial empiric therapy for invasive disease.
Second, communities with a high percentage of
drug-resistant S. pneumoniae may benefit from
efforts to reduce inappropriate antibiotic prescrip-
tions. Increased drug-resistant S. pneumoniae
carriage is directly related to antibiotic therapy,
and reduced antimicrobial use in the community
can decrease rates of antimicrobial resistance
(13-16). Finally, clinicians in areas with a low
percentage of drug-resistant S. pneumoniae and
minimal penicillin resistance might gain
confidence in treating presumptive outpatient
infections with empiric penicillin therapy, thereby
reducing the risk for multidrug resistance.
Despite the clinical and public health
importance of drug-resistant S. pneumoniae
surveillance, community-specific surveillance data
are not uniformly available. A 1996 study
determined that 54% of states either conducted
or were planning to implement surveillance for
drug-resistant S. pneumoniae by June 1997 (17).
Our study supports the usefulness of S. pneumoniae
antibiogram data, commonly available at many
hospitals, in estimating the community-specific
proportion of penicillin-susceptible S. pneumoniae.
In no instance did hospital-specific penicillin
susceptibility estimates from the two methods
differ statistically. More importantly, the overall
Portland penicillin susceptibility proportions
determined by the active surveillance and
antibiogram methods were statistically comparable.
Antibiogram data also hold promise for
estimating S. pneumoniae susceptibilities to
other antimicrobial drugs. The hospital-specific
proportion of S. pneumoniae isolates susceptible
to cefotaxime and trimethoprim-
sulfamethoxazole did not differ for the two
methods in hospitals where comparisons were
possible. The erythromycin susceptibility pro-
portions by antibiogram and active surveillance
were statistically comparable at each of the
hospitals for which erythromycin data were
available, except for hospital C. The reason for
this discordance is not clear but may be
influenced by statistical chance.
Time and financial requirements for the
antibiogram method were minimal and probably
within reach of many local health departments.
Laboratory effort was limited to mailing a current
antibiogram to the health department. However,
the antibiogram method can only estimate the
proportion of drug-resistant S. pneumoniae in a
community. The active surveillance system collects
patient-specific (e.g., risk factors, demographics)
and infection-specific information, permits
serotyping and molecular analysis of isolates,
provides data on the actual S. pneumoniae
disease effect in the population, permits evaluation
of targeted vaccination campaigns and antimicro-
bial guideline efforts, provides specific MIC data
for a range of antimicrobial agents, and allows for
validation of alternative surveillance methods.
Prior surveillance studies have documented
equal or greater proportions of penicillin-
resistant isolates collected from nonsterile sites
than from sterile sites (18,19). Our active
surveillance system captures only isolates from
sterile sites collected from invasive S. pneumoniae
disease. Most isolates in the antibiograms were
from noninvasive diseases and nonsterile sites.
Our study showed no statistical difference
between the proportion of penicillin-susceptible
S. pneumoniae determined by either method and
therefore no difference between the penicillin-
susceptible proportion of invasive and noninvasive
isolates. Ninety-six percent of our active
surveillance isolates were from outpatients or
inpatients hospitalized less than 48 hours and
are unlikely to represent nosocomial infections.
These data support the traditional epidemiologic
characterization of S. pneumoniae as a community
rather than nosocomially acquired organism.
Several potential limitations deserve
comment. The active surveillance system had a
case-isolate recovery rate of 67%. The current
performance indicator for the active surveillance
system, instituted in 1998, is a case-isolate
recovery rate of 85% (A. Schuchat, pers. comm.)
We were unable to characterize the susceptibilities
of the missing isolates, which may have biased
our active surveillance results. Antibiograms
were tabulated from all isolates submitted to a
particular hospital laboratory. Multiple isolates
from a single patient may have disproportionately
influenced these results. Unlike the active
surveillance system, in which chart reviews
excluded nonresidents, antibiogram data may
have included isolates from patients who were
not Portland-area residents and should not have
been included in Portland S. pneumoniae
antimicrobial-susceptibility results. We were
unable to estimate the number of duplicate693 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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isolates or non-Portland-area residents in our
antibiogram data.
This study suggests that antibiogram data
already available in hospitals may be useful in
estimating the community-specific proportion of
drug-resistant  S. pneumoniae. We recommend
further validation of these results at sites where
active surveillance and antibiogram data can be
directedly compared. The most effective use of
antibiogram drug-resistant S. pneumoniae surveil-
lance  may require that hospitals routinely and
consistently perform S. pneumoniae susceptibility
testing to multiple antimicrobial drugs. Commu-
nities considering this surveillance method may
need to work with local hospitals to develop a
cost-effective susceptibility testing regimen. Al-
though yielding less information than active
surveillance, antibiogram surveillance might be
most useful in communities where hospital
antibiogram data are available but more
intensive  surveillance is limited by a lack of
financial or personnel resources.
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